NQTrp (Synonyms: 1,4-Naphthoquinon-2-yl-L-tryptophan) |
| Katalog-Nr.GC17037 |
NQTrp, ein aromatisches Naphthochinon-Tryptophan-HybridmolekÜl, ein Inhibitor der Aggregation des Tau-Proteins mit generischer anti-amyloidogener Wirkung.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 185351-19-3
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
NQTrp, also known as 1,4-naphthoquinon-2-yl-L-tryptophan, is an inhibitor of the Alzheimer’s disease-associated β-amyloid [1].
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder and the early soluble oligomeric species of Aβ plays a fundamental role in the pathogenesis of AD [1]. The Aβ peptide results from the cleavage of the amyloid precursor protein (APP) by the β- and γ-secretases and the predominant Aβ peptides found in the brain are 40 (Aβ1-40) and 42 (Aβ1-42) residues [2].
In the oligomer inhibition assay and ThT fibril inhibition assay, NQTrp completely inhibited Aβ oligomerization and fibrillization. In cultured neural cells, NQTrp dose-dependently inhibited Aβ to assemble into toxic oligomers. In rat PC12 neuronal cell line, NQTrp significantly inhibited the cytotoxic effect of the Aβ oligomers and increased the viability of the cells [1].
In a Drosophila model of AD, NQTrp prolonged the life span of Aβ1–42-expressing flies. Aβ1–42-expressing flies with NQTrp displayed dramatic improvement, behaving almost identical to the control classes. The brains of these flies showed a significant reduction in oligomeric species of Aβ [1].
References:
[1]. Scherzer-Attali R, Pellarin R, Convertino M, et al. Complete phenotypic recovery of an Alzheimer's disease model by a quinone-tryptophan hybrid aggregation inhibitor. PLoS One. 2010 Jun 14;5(6):e11101.
[2]. Zhang T, Xu W, Mu Y, et al. Atomic and dynamic insights into the beneficial effect of the 1,4-naphthoquinon-2-yl-L-tryptophan inhibitor on Alzheimer's Aβ1-42 dimer in terms of aggregation and toxicity. ACS Chem Neurosci. 2014 Feb 19;5(2):148-59.
| Cas No. | 185351-19-3 | SDF | |
| Überlieferungen | 1,4-Naphthoquinon-2-yl-L-tryptophan | ||
| Chemical Name | N-(1,4-dihydro-1,4-dioxo-2-naphthalenyl)-L-tryptophan | ||
| Canonical SMILES | O=C(C=C(N[C@H](C(O)=O)CC1=CNC2=C1C=CC=C2)C3=O)C4=C3C=CC=C4 | ||
| Formula | C21H16N2O4 | M.Wt | 360.4 |
| Löslichkeit | ≤1mg/ml in ethanol;20mg/ml in DMSO;20mg/ml in dimethyl formamide | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.7747 mL | 13.8735 mL | 27.7469 mL |
| 5 mM | 554.9 μL | 2.7747 mL | 5.5494 mL |
| 10 mM | 277.5 μL | 1.3873 mL | 2.7747 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 32 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *